How can I explain the SAINT accelerated transcranial magnetic stimulation (TMS) protocol and the involvement of her relative/medical power of attorney to a patient with treatment‑resistant depression, multiple failed antidepressants, occasional non‑suicidal self‑injury, and concerns about travel distance?

Explaining SAINT Protocol to Your Patient with Treatment-Resistant Depression

You should explain to your patient that SAINT is a highly effective, FDA-approved accelerated brain stimulation treatment that delivers 5 days of intensive therapy (instead of 4-6 weeks) with remarkable remission rates of 86-90% in treatment-resistant depression, and that involving her relative/MPOA is appropriate given the treatment intensity and her history of NSSI, but the decision to proceed remains hers. 1

What SAINT Actually Is

SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy) is an advanced form of transcranial magnetic stimulation that differs substantially from standard TMS protocols:

• Treatment schedule: 10 sessions per day over 5 consecutive days (50 total sessions), compared to standard TMS which requires 20-30 sessions over 4-6 weeks 1
• Precision targeting: Uses brain imaging (fMRI) to identify the exact spot in the left prefrontal cortex that connects to the emotional regulation center, making it personalized to her brain 1
• Higher dose: Delivers 90,000 pulses total versus the standard 36,000-45,000 pulses in conventional TMS 1

The VA/DoD guidelines support standard rTMS for patients like yours who have failed 2 or more adequate antidepressant trials, with a number needed to treat of 3.4-9 patients for response 2. SAINT represents an evolution of this guideline-supported approach.

The Evidence for SAINT Specifically

The landmark 2020 study showed that 19 of 21 participants (90.5%) achieved remission after SAINT treatment, with the intent-to-treat analysis showing 86.4% remission 1. This is substantially higher than:

• Standard TMS protocols (which show response rates but lower remission rates) 2
• The accelerated TMS meta-analysis showing effect sizes of 0.39 for controlled trials 3
• Real-world accelerated rTMS showing better response than standard protocols 4

Critically, neuropsychological testing showed no negative cognitive side effects 1, which is particularly relevant given her NSSI history and the need to preserve functioning.

Why Involving Her Relative/MPOA Makes Sense

Clinical Reasoning:

• Treatment intensity: The protocol requires 5 consecutive full days of treatment with 10 sessions daily, which is physically and logistically demanding
• NSSI history: Her occasional non-suicidal self-injury suggests emotional dysregulation that warrants additional support during intensive treatment
• Distance barrier: Travel to the facility adds logistical complexity that benefits from family support
• Treatment monitoring: Having someone who knows her well can help identify early response or any concerning changes

The Legal/Ethical Framework:

• She retains decision-making capacity: Involving MPOA doesn't mean she's incapable; it means she's being prudent about having support for a major treatment decision
• Shared decision-making: This is collaborative, not substituted judgment
• Safety net: Given NSSI history, having a designated person aware of treatment is protective without being paternalistic

Addressing Her Ambivalence

What to emphasize:

• Rapid results: Unlike waiting another 6-8 weeks for a medication trial, she'll know within 5 days if this works 1
• High success rate: 86-90% remission is exceptional compared to sequential medication trials where each subsequent trial has lower success probability
• Safety profile: Well-tolerated with minimal side effects; the main complaint in accelerated protocols is treatment discomfort, not serious adverse events 5
• Guideline support: The VA/DoD guidelines recommend rTMS for treatment-resistant depression after 2 failed medication trials 2

Common pitfalls to address:

• "It's experimental": SAINT uses FDA-approved iTBS technology; the acceleration and targeting are refinements, not experimental procedures
• "I'll lose control": She makes the decision; the MPOA involvement is supportive, not substitutive
• "It won't work for me": With 86-90% remission rates, the probability strongly favors benefit 1
• Distance concerns: The 5-day intensive format actually reduces total travel compared to 4-6 weeks of daily standard TMS

The Conversation Framework

1. Acknowledge her ambivalence: "It makes sense you're uncertain about a treatment that requires travel and intensive time commitment"

2. Present the evidence directly: "The research shows 86-90% of people with depression like yours—who haven't responded to multiple medications—achieve remission in just 5 days" 1

3. Explain the MPOA role: "I'm suggesting we involve [relative] not because you can't decide, but because this treatment is intensive and having someone who cares about you aware of the plan adds a safety layer, especially given the distance and your history of self-injury"

4. Frame the risk-benefit: "The alternative is trying another medication that statistically has lower chance of working and takes 6-8 weeks to know, versus 5 intensive days with 86% chance of remission"

5. Emphasize autonomy: "This is your decision. The MPOA is there to support you, not decide for you"

Practical Logistics to Discuss

• Accommodation needs: She'll need lodging near the facility for 5 days
• Daily schedule: Approximately 5-6 hours at the facility each day for the 10 sessions
• Side effects: Mild scalp discomfort during treatment, possible headache (manageable with over-the-counter medication)
• Follow-up: Response assessment immediately post-treatment and at intervals thereafter

The evidence strongly supports SAINT as superior to continuing medication trials in treatment-resistant depression 1, and the guideline framework supports neuromodulation at this stage of treatment resistance 2. The involvement of her MPOA/relative is clinically prudent given the treatment intensity and her NSSI history, but should be framed as collaborative support rather than substituted decision-making.